|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A Paradigm for Controlling Virtual Humans in Urban Environment Simulatlons显示文摘 | Farenc N Musse S R Schweiss E Kallmann | 2000 | Applied Artificial Intelligence2000，14，1： | 1 |
| 2 | Ghrelin,macronutrient intake and dietary preferences in Long-Evans rats显示文摘 | BECK B MUSSE N STRICKER-KRONGRAD A | 2002 | Biochen Biophys Res Commun2002，292，： | 1 |
| 3 | Soluble Fas is a marker of coronary a rtery disease in patients with end stage renal disease显示文摘 | Hebert MJ Musse M Vignealt N | | Am J Kidney Dis0，38，6： | 1 |
| 4 | Ghrelin,macronutrient intake and dietary preferences in long-evans rats显示文摘 | Beck B Musse N Stricker-Krongrad A | 2002 | Biochem Biophys Res Commun2002，292，4： | 1 |
| 5 | Ghrelin, macronutrient intake and dietary preferences in long-evans rats 显示文摘 | Beck B Musse N Stricker Krongrad A | 2002 | Biochem Biophys Res Commun2002，292，： | 1 |
| 6 | Ghrelin, macronutrient intake and dietary preferences in Long - Evans rats 显示文摘 | Beck B Musse N Stricker - Krongrad A | 2002 | Biochemical and biophysical re- search communications2002，292，4： | 1 |
| 7 | Ghrelin,macronutrient intake and dietary preferences in Long-evans rats显示文摘 | Beck B Musse N Stricker-Krongrad A | | 0，，04： | 1 |
| 8 | Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial显示文摘 | Paul E Goss Dawn L Hershman Angela M Cheung James N Ingle Sundeep Khosla Vered Stearns Haji Chalchal Kendrith Rowland Hyman B Muss Hannah M Linden Judite Scher Kathleen I Pritchard Catherine R Elliott Tanja Badovinac-Crnjevic Jessica St Louis Judith-Anne | 2014 | Lancet Oncology2014，，： | 1 |
| 9 | Competing risks of death in younger and older postmenopausal breast cancer patients显示文摘AIM: To show a new paradigm of simultaneously testing whether breast cancer therapies impact other causes of death. METHODS: MA.14 allocated 667 postmenopausal women to 5 years of tamoxifen 20 mg/daily ± 2 years of octreotide 90 mg, given by depot intramuscular injections monthly. Event-free survival was the primary endpoint of MA.14; at median 7.9 years, the tamoxifen+octreotide and tamoxifen arms had similar event-free survival(P = 0.62). Overall survival was a secondary endpoint, and the two trial arms also had similar overall survival(P = 0.86). We used the median 9.8 years follow-up to examine by intention-to-treat, the multivariate time-to-breast cancer-specific(Br Ca) and other cause(OC) mortality with log-normal survival analysis adjusted by treatment and stratification factors. We tested whether baseline factors including Insulin-like growth factor 1(IGF1), IGF binding protein-3, C-peptide, body mass index, and 25-OH vitamin D were associated with(1) all cause mortality, and if so; and(2) cause-specific mortality. We also fit step-wise forward cause-specific adjusted models.RESULTS: The analyses were performed on 329 patients allocated tamoxifen and 329 allocated tamoxifen+octreotide. The median age of MA.14 patients was 60.1 years: 447(82%) < 70 years and 120(18%) ≥ 70 years. There were 170 deaths: 106(62.3%) BrC a; 55(32.4%) OC, of which 24 were other malignancies, 31 other causes of death; 9(5.3%) patients with unknown cause of death were excluded from competing risk assessments. BrC a and OC deaths were not significantly different by treatment arm(P = 0.40): tamoxifen patients experienced 50 BrC a and 32 OC deaths, while tamoxifen + octreotide patients experienced 56 Br Ca and 23 OC deaths. Proportionately more deaths(P = 0.004) were from BrC a for patients< 70 years, where 70% of deaths were due to Br Ca, compared to 54% for those ≥ 70 years of age. The proportion of deaths from OC increased with increasing body mass index(BMI)(P = 0.02). Higher pathologic T and N were associated with more BrC a deaths(P < 0.0001 and 0.002, respectively). The cumulative hazard plot for Br Ca and OC mortality indicated the concurrent accrual of both types of death throughout followup, that is the existence of competing risks of mortality. MA.14 therapy did not impact mortality(P = 0.77). Three baseline patient and tumor characteristics were differentially associated with cause of death: older patients experienced more OC(P = 0.01) mortality; patients with T1 tumors and hormone receptor positive tumors had less BrC a mortality(respectively, P = 0.01, P = 0.06). Additionally, step-wise cause-specific models indicated that patients with node negative disease experienced less BrC a mortality(P = 0.002); there was weak evidence that, lower C-peptide(P = 0.08) was associated with less BrC a mortality, while higher BMI(P = 0.01) was associated with worse OC mortality.CONCLUSION: We demonstrate here a new paradigm of simultaneous testing of therapeutics directed at multiple diseases for which postmenopausal women are concurrently at risk. Octreotide LAR did not significantly impact breast cancer or other cause mortality, although different baseline factors influenced type of death. | Judy-Anne W Chapman Kathleen I Pritchard Paul E Goss James N Ingle Hyman B Muss Susan F Dent Ted A Vandenberg Brian Findlay Karen A Gelmon Carolyn F Wilson Lois E Shepherd Michael N Pollak | 2014 | World Journal of Clinical Oncology2014，5，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员